- Home
- FEBO vs ACXP Comparison
FEBO vs ACXP Comparison
Compare FEBO & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FEBO | ACXP |
|---|---|---|
| Founded | 1993 | 2017 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.8M | 3.8M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | FEBO | ACXP |
|---|---|---|
| Price | $1.24 | $4.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $143.67 |
| AVG Volume (30 Days) | 8.9K | ★ 5.8M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.61 | $0.29 |
| 52 Week High | $1.48 | $8.34 |
Technical Indicators
Market Signals| Indicator | FEBO | ACXP |
|---|---|---|
| Relative Strength Index (RSI) | 62.15 | 66.04 |
| Support Level | $1.04 | $3.98 |
| Resistance Level | $1.26 | $5.28 |
| Average True Range (ATR) | 0.06 | 0.70 |
| MACD | 0.02 | 0.36 |
| Stochastic Oscillator | 86.68 | 69.04 |
Price Performance
Historical ComparisonAbout FEBO Fenbo Holdings Limited
Fenbo Holdings Ltd is a company engaged in producing premium personal care electric appliances, principally electrical hair styling products such as straighteners, curlers, trimmers, etc., and toy products to overseas markets. It manufactures and sells products such as Straightener, Mini Straightener, and Curling Iron.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.